Literature DB >> 20826791

An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy.

Christopher R Orr1, Heather L Montie, Yuhong Liu, Elena Bolzoni, Shannon C Jenkins, Elizabeth M Wilson, James D Joseph, Donald P McDonnell, Diane E Merry.   

Abstract

Polyglutamine expansion within the androgen receptor (AR) causes spinal and bulbar muscular atrophy (SBMA) and is associated with misfolded and aggregated species of the mutant AR. We showed previously that nuclear localization of the mutant AR was necessary but not sufficient for SBMA. Here we show that an interdomain interaction of the AR that is central to its function within the nucleus is required for AR aggregation and toxicity. Ligands that prevent the interaction between the amino-terminal FXXLF motif and carboxyl-terminal AF-2 domain (N/C interaction) prevented toxicity and AR aggregation in an SBMA cell model and rescued primary SBMA motor neurons from 5α-dihydrotestosterone-induced toxicity. Moreover, genetic mutation of the FXXLF motif prevented AR aggregation and 5α-dihydrotestosterone toxicity. Finally, selective androgen receptor modulators, which prevent the N/C interaction, ameliorated AR aggregation and toxicity while maintaining AR function, highlighting a novel therapeutic strategy to prevent the SBMA phenotype while retaining AR transcriptional function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20826791      PMCID: PMC2975181          DOI: 10.1074/jbc.M110.146845

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain.

Authors:  B He; J A Kemppainen; J J Voegel; H Gronemeyer; E M Wilson
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

2.  FOXO3a is broadly neuroprotective in vitro and in vivo against insults implicated in motor neuron diseases.

Authors:  Jelena Mojsilovic-Petrovic; Natalia Nedelsky; Marco Boccitto; Itzhak Mano; Savvas N Georgiades; Weiguo Zhou; Yuhong Liu; Rachael L Neve; J Paul Taylor; Monica Driscoll; Jon Clardy; Diane Merry; Robert G Kalb
Journal:  J Neurosci       Date:  2009-06-24       Impact factor: 6.167

3.  Transcriptional synergy between melanoma antigen gene protein-A11 (MAGE-11) and p300 in androgen receptor signaling.

Authors:  Emily B Askew; Suxia Bai; Amanda J Blackwelder; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2010-05-06       Impact factor: 5.157

4.  Re: Furutani T, Takeyama K-i., Tanabe M, Koutoku H, Ito S, Taniguchi N, Suzuki E, Kudoh M, Shibasaki M, Shikama H, and Kato S (2005) Human expanded polyglutamine androgen receptor mutants in neurodegeneration as a novel ligand target. J Pharmacol Exp Ther 315:545-552; doi:10.1124/jpet.105.087643.

Authors: 
Journal:  J Pharmacol Exp Ther       Date:  2014-03       Impact factor: 4.030

5.  Identification of a novel phosphorylation site in human androgen receptor by mass spectrometry.

Authors:  Z Zhu; R R Becklin; D M Desiderio; J T Dalton
Journal:  Biochem Biophys Res Commun       Date:  2001-06-15       Impact factor: 3.575

6.  FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor.

Authors:  B He; J A Kemppainen; E M Wilson
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

7.  Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy.

Authors:  Heather L Montie; Maria S Cho; Latia Holder; Yuhong Liu; Andrey S Tsvetkov; Steven Finkbeiner; Diane E Merry
Journal:  Hum Mol Genet       Date:  2009-03-11       Impact factor: 6.150

8.  Consequences of poly-glutamine repeat length for the conformation and folding of the androgen receptor amino-terminal domain.

Authors:  Philippa Davies; Kate Watt; Sharon M Kelly; Caroline Clark; Nicholas C Price; Iain J McEwan
Journal:  J Mol Endocrinol       Date:  2008-09-01       Impact factor: 5.098

9.  Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice.

Authors:  Xiaofeng Gu; Erin R Greiner; Rakesh Mishra; Ravindra Kodali; Alex Osmand; Steven Finkbeiner; Joan S Steffan; Leslie Michels Thompson; Ronald Wetzel; X William Yang
Journal:  Neuron       Date:  2009-12-24       Impact factor: 17.173

10.  Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism.

Authors:  Ashwani K Thakur; Murali Jayaraman; Rakesh Mishra; Monika Thakur; Veronique M Chellgren; In-Ja L Byeon; Dalaver H Anjum; Ravindra Kodali; Trevor P Creamer; James F Conway; Angela M Gronenborn; Ronald Wetzel
Journal:  Nat Struct Mol Biol       Date:  2009-03-08       Impact factor: 15.369

View more
  32 in total

1.  SIRT1 modulates aggregation and toxicity through deacetylation of the androgen receptor in cell models of SBMA.

Authors:  Heather L Montie; Richard G Pestell; Diane E Merry
Journal:  J Neurosci       Date:  2011-11-30       Impact factor: 6.167

2.  Gain in transcriptional activity by primate-specific coevolution of melanoma antigen-A11 and its interaction site in androgen receptor.

Authors:  Qiang Liu; Shifeng Su; Amanda J Blackwelder; John T Minges; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2011-07-05       Impact factor: 5.157

3.  Attacking the flank: targeting new pathways in SBMA.

Authors:  Diane E Merry
Journal:  Nat Med       Date:  2012-10       Impact factor: 53.440

Review 4.  Spinal and Bulbar Muscular Atrophy.

Authors:  Christopher Grunseich; Kenneth H Fischbeck
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

5.  Deubiquitinase USP7 contributes to the pathogenicity of spinal and bulbar muscular atrophy.

Authors:  Anna Pluciennik; Yuhong Liu; Elana Molotsky; Gregory B Marsh; Bedri Ranxhi; Frederick J Arnold; Sophie St-Cyr; Beverly Davidson; Naemeh Pourshafie; Andrew P Lieberman; Wei Gu; Sokol V Todi; Diane E Merry
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

Review 6.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

Review 7.  The Role of the Protein Quality Control System in SBMA.

Authors:  Paola Rusmini; Valeria Crippa; Riccardo Cristofani; Carlo Rinaldi; Maria Elena Cicardi; Mariarita Galbiati; Serena Carra; Bilal Malik; Linda Greensmith; Angelo Poletti
Journal:  J Mol Neurosci       Date:  2015-11-14       Impact factor: 3.444

Review 8.  Targeted Molecular Therapies for SBMA.

Authors:  Carlo Rinaldi; Bilal Malik; Linda Greensmith
Journal:  J Mol Neurosci       Date:  2015-11-17       Impact factor: 3.444

9.  Antiandrogen flutamide protects male mice from androgen-dependent toxicity in three models of spinal bulbar muscular atrophy.

Authors:  Kayla J Renier; Sandra M Troxell-Smith; Jamie A Johansen; Masahisa Katsuno; Hiroaki Adachi; Gen Sobue; Jason P Chua; Hong Sun Kim; Andrew P Lieberman; S Marc Breedlove; Cynthia L Jordan
Journal:  Endocrinology       Date:  2014-04-17       Impact factor: 4.736

Review 10.  Polyglutamine androgen receptor-mediated neuromuscular disease.

Authors:  Elisa Giorgetti; Andrew P Lieberman
Journal:  Cell Mol Life Sci       Date:  2016-05-17       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.